This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma | MicrobiomeTrials
← Back to trials NCT02911142
Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma Recruiting PHASE1, PHASE2 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2017-07-03Est. Completion: 2024-10-01
Enrollment target: 17 participantsLocations National Institutes of Health Clinical Center, Bethesda, Maryland, United States Other microbiome trials you might be interested in HIV Kaposi's Sarcoma Lymphomas Multicentric Castleman's Disease Primary Effusion Lymphoma
BACKGROUND:
* A number of important scientific advances can be made through the study of blood, bone marrow, tumor, or …
Bethesda, United States
KSHV Inflammatory Cytokine Syndrome (KICS) KSHV HHV-8
Background:
\- KSHV inflammatory cytokine syndrome (KICS) is a newly recognized disease caused by Kaposi sarcoma-associ…
Bethesda, United States Est. completion Dec 31, 2028
AIDS-related Non-Hodgkin Lymphoma AIDS-related Plasmablastic Lymphoma AIDS-related Primary Effusion Lymphoma HIV Infection
This pilot clinical trial studies gene therapy after frontline chemotherapy in treating patients with acquired immune de…
Duarte, United States Est. completion Jul 6, 2027